DLA Piper advised Cantor Equity Partners III, Inc., a special purpose acquisition company sponsored by an affiliate of Cantor Fitzgerald, in its entry into a business combination agreement with AIR Limited, a global provider of hookah and advanced inhalation technologies. Upon closing, the transaction will result in the combined company, AIR Global Limited, becoming publicly listed in the United States with an enterprise value of US$1.749 billion. The DLA Piper team included Partners Stephen Alicanti and Sidney Burke (both New York), and Associates Carina Meleca (New York), Nick Young (Phoenix), and Luke Postma (Seattle). Additional support was provided by DLA Piper Partners William Bartow, Jae Kim (both Philadelphia), Paolo Morante (New York), Julia Kovacs, Aurelie Ercoli (both Washington, DC), Victoria Richter (Chicago), and Sarah Tauman (San Francisco); Of Counsels Arlette Grabczynska (Chicago), Michael Madigan (New York), and Priya Narahari (Philadelphia); Senior Attorney Brittany Ellenberg (San Francisco); and Associates James Duchesne (Washington, DC), Jianyuan Hua (New York), Bianca LaCaille, Sarah Cooper (both Seattle), Irina Rudenko (Dallas), and Becca Xu (San Diego). With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 15 consecutive years, according to Mergermarket, and ranked as number one in VC, PE, and M&A in combined global deal volume, according to PitchBook. DLA Piper enables issuers and underwriters to execute complex securities transactions throughout the world. We offer tactical approaches to financings across equity and debt capital markets, alternative public offerings (de-SPACs, reverse mergers, and direct listings), and other transformative corporate transactions. Lawyers in our Corporate Governance practice act as outside corporate and securities counsel to a wide range of reporting companies by guiding clients through securities offerings and nuanced disclosure, governance, and compliance matters under SEC, Nasdaq, and NYSE rules and regulations. Boards of directors turn to us to navigate complex transactions, special investigations, and challenging risk oversight matters. Please visit Capital Markets and Public Company Advisory and Market Edge. Related professionals:Stephen AlicantiSidney BurkeCarina MelecaNicholas YoungLuke PostmaWilliam BartowJae KimPaolo MoranteJulia KovacsAurélie ErcoliVictoria RichterSarah TaumanArlette GrabczynskaMichael MadiganPriya NarahariJames DuchesneJianyuan HuaBianca LaCailleSarah CooperIrina RudenkoBecca Xu

Baker McKenzie advised the current shareholders on the sale of all their equity interests in Medistream SA, a Swiss corporation holding all equity interests in Citieffe SRL, an Italian medical devices manufacturer, and its subsidiaries in the United States and Mexico (“Citieffe Group”), to Poly Medicure B.V., Amsterdam, Netherlands, a wholly owned subsidiary of Poly Medicure Limited, an Indian public company (“PolyMed”). Funds advised by ARCHIMED, a global private equity firm focused on the healthcare sector, were the majority shareholders in Citieffe Group.

The Citieffe Group is an Italy-based manufacturer specializing in the orthopedic trauma and extremities segment, with a direct presence in Italy, the United States and Mexico, as well as distribution across 25 countries. The transaction was completed on 6 November 2025.

This strategic acquisition provides PolyMed with a gateway into the global orthopedics market, particularly in the trauma and extremities segment — the fastest growing and most resilient category within orthopedics. As part of PolyMed, the Citieffe Group is expected to benefit from enhanced R&D and manufacturing capabilities, including potential cost efficiencies through operations in India.

Baker McKenzie advised the shareholders of Citieffe Group, including ARCHIMED, on all legal and tax aspects of the transaction.

M&A Partners Alexander Fischer and Olha Deminaniuk led the team, which included Alexander Blaeser (partner, M&A), Susanne Liebel-Kotz (partner, tax), Vinzenz Sutter (associate, M&A), Kiara Sharifi (associate, M&A), Kaspar Projer (associate, Dispute Resolution/International Commercial & Trade) and Anna Zellweger (associate, International Commercial & Trade).

About ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

About Citieffe Group

Founded in 1962 in Italy, Citieffe Group is a company specializing in extremity orthopedics, offering materials for trauma management, including internal and external fixation, prostheses and general surgical instruments. The company develops, manufactures and sells products such as intramedullary nails and reconstruction-oriented external fixation devices, some of which are patented.